Planz Viktoria, Wang Jing, Windbergs Maike
Institute of Pharmaceutical Technology and Buchmann Institute for Molecular Life Sciences, Goethe University, 60438 Frankfurt am Main, Germany; Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Department of Drug Delivery (DDEL), Saarland University, 66123 Saarbruecken, Germany.
Institute of Pharmaceutical Technology and Buchmann Institute for Molecular Life Sciences, Goethe University, 60438 Frankfurt am Main, Germany; Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Department of Drug Delivery (DDEL), Saarland University, 66123 Saarbruecken, Germany.
J Pharmacol Toxicol Methods. 2018 Jan-Feb;89:19-25. doi: 10.1016/j.vascn.2017.10.003. Epub 2017 Oct 14.
Predictive in vitro testing of novel wound therapeutics requires adequate cell-based bio-assays. Such assays represent an integral part during preclinical development as pre-step before entering in vivo studies. Simple "scratch tests" based on defected skin cell monolayers exist, however these can solely be used for testing liquids, as cell monolayer destruction and excessive hydration limit their applicability for (semi-)solid systems like wound dressings. In this context, a cell-based wound healing assay is introduced for rapid and predictive testing of wound therapeutics independent of their physical state in a bio-relevant environment.
A novel wound healing assay was established for bio-relevant and predictive testing of (semi-) solid wound therapeutics.
The assay allows for physiologically relevant hydration of the tested wound therapeutics at the air-liquid interface and their removal without cell monolayer disruption. In a proof-of-concept study, the applicability and discriminative power could be demonstrated by examining unloaded and drug-loaded wound dressings with two different established wound healing actives (dexpanthenol and metyrapone) and their effect on skin cell behavior. The influence of the released drug on the cells´ healing behavior could successfully be monitored over time. Wound size assessment after 96h resulted in an eight fold smaller wound area for drug treated models compared to the ones treated with unloaded fibers and non-treated wounds.
This assay provides valuable first insights towards the establishment of a valid screening and evaluation tool for preclinical wound therapeutic development from liquid to (semi-)solid systems to improve predictability in a simple, yet standardized way.
新型伤口治疗药物的体外预测性测试需要合适的基于细胞的生物测定法。此类测定法是临床前开发中不可或缺的一部分,是进入体内研究之前的预步骤。基于受损皮肤细胞单层的简单“划痕试验”确实存在,然而,由于细胞单层破坏和过度水合作用限制了它们对伤口敷料等(半)固体系统的适用性,这些试验只能用于测试液体。在此背景下,引入了一种基于细胞的伤口愈合测定法,用于在生物相关环境中对伤口治疗药物进行快速且具有预测性的测试,而不受其物理状态的影响。
建立了一种新型伤口愈合测定法,用于对(半)固体伤口治疗药物进行生物相关且具有预测性的测试。
该测定法能够在气液界面使受试伤口治疗药物实现生理相关的水合作用,并在不破坏细胞单层的情况下将其去除。在一项概念验证研究中,通过使用两种不同的已确立的伤口愈合活性物质(泛醇和甲吡酮)检测未负载和负载药物的伤口敷料及其对皮肤细胞行为的影响,证明了该测定法的适用性和区分能力。随着时间的推移,可以成功监测释放的药物对细胞愈合行为的影响。96小时后的伤口大小评估结果显示,与使用未负载纤维处理的模型和未处理的伤口相比,药物处理模型的伤口面积缩小了八倍。
该测定法为建立一个有效的筛选和评估工具提供了有价值的初步见解,该工具可用于临床前伤口治疗从液体系统到(半)固体系统的开发,以一种简单但标准化的方式提高预测性。